Twitter Linkedin Instagram
Twitter Linkedin Instagram

MD Education is proud to introduce a new, virtual education initiative for HCPs in MDS: the MDS Clinical Roadmap.

July 2023-2024, Chairperson Dr. Rami Komrokji, MD and a guest clinical expert will dive deep into a trending MDS topic through a 20- minute slide presentation followed by a 10-minute Q&A session.

This refreshing, conversation style presentation is both engaging and invigorating, presenting the latest in MDS clinical care.

Register here!
  • 13 leading specialists in MDS
  • 13 educational discussions online
  • 20-minute presentations with slides followed by a 10-minute Q&A session with one chair and two guest speakers every month

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

FEBRUARY

From normal hematopoiesis to MDS: clonality and inflammation?

Uma Borate

Ohio State University james Cancer Hospital, Columbus, Ohio, USA

Video & Information

MARCH

MDS Diagnosis and risk stratification: Gettingafacelift

Amy Dezern

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Video & Information

MAY

Luspatercept: where to fit the new kid on the block?

Pierre Fenaux

Hospital Saint Louis, Paris, France

Video & Information

JUNE

HMA: Do we know how and when to use in MDS after 2 decades?

Mikkael Sekeres

University of Miami Miller School of Medicine, Florida, USA

Video & Information

JULY

Allogeneic stem cell transplant: how can we cure more patients?

Bart Scott

University of Washington Medical Center, Seattle, Washington, USA

Video & Information

AUGUST

Role ofvenetoclax in MDS: Playing out of the box?

Guillermo Garcia- Manero

MD Anderson Cancer Center, Houston, Texas, USA

Video & Information

SEPTEMBER

Novel agents for higher risk MDS: be on the look?

David Sallman

Moffitt Cancer Center, Tampa, Florida, USA

Video & Information

OCTOBER

Managing isolated neutropenia and thrombocytopenia in Lower risk MDS

Valeria Santini

University of Florence, Italy

Video & Information

NOVEMBER

Immunosuppressive therapy in MDS

Yazan Migdady

Oregon Health & Science University, Portland, Oregon, USA

Video & Information

DECEMBER

Novel agents for lower risk MDS: be on the look?

Hetty Carraway

Cleveland Clinic, Ohio, USA

Video & Information

January 2024

Response to treatment in MDS: how to assess benefit in clinical trials and practice

Andrew Brunner

Andrew Brunner

Massachusetts General Hospital, Boston, USA

Video & Information

FEBRUARY 2024

Entering the Era of molecular inspired MDS risk stratification: who are the contenders?

Aziz Nazha

Amazon Web Services, Westlake, Ohio, USA

Video & Information

FACULTY REVIEW

FACULTY GROUP REVIEW AT THE END OF THE 12 MONTHS TO REFLECT ON KEY DEVELOPMENTS

If you would like additional information or have any questions, please email:

office@md-education.com

Get in touch with us

ORGANISED BY:

UK Office

MD Education Ltd
4/4a Bloomsbury Square, London , WC1A 2RP

USA Office

MD Education USA LLC,
4600 140th Avenue North, Suite 180,  Clearwater, Florida 33762

Privacy Policy  |  Cookie Policy

Developed by Unet

Uma Borate
Uma Borate

Ohio State University james Cancer Hospital, Columbus, Ohio, USA

Dr. Borate is a practicing hematologist-oncologist at Oregon Health & Science University who specializes in taking care of patients with aggressive blood cancers, especially acute leukemias. She feels privileged to be involved in the care of cancer patients and be a partner in their fight against their disease. She believes the treatment of a patient always involves their loved ones and the health care team who all work together to help the patient achieve his/her goals of care. In her spare time, she loves to hike, run, read and spend time with her two daughters and husband.

From normal hematopoiesis to MDS: clonality and inflammation?

Rami Komrokji Preview
Uma Borate Preview
Uma Borate Presentation
Q&A
Uma Borate Slide

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Uma Borate

Ohio State University james Cancer Hospital, Columbus, Ohio, USA

Amy DeZern

Amy Dezern

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Dr. Amy DeZern is a hematologist and medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine. Dr. DeZern’s primary clinical and research interests are focused on bone marrow failure disorders. She has expertise in the diagnosis and treatment of myelodysplastic syndromes (MDS), aplastic anemia (AA), and paroxysmal nocturnal hemoglobinuria (PNH) as well as acute leukemias. She is an active clinician scientist who specializes in clinical trials of diagnostics and therapeutics for these disorders. She has been the principle investigator for over 40 single center and multicenter clinical trials in MDS and AA.  These investigator-led initiatives focus is on transplant therapies in AA and novel therapeutics (Phase 1-3 trials) in MDS.  Additionally, Dr. DeZern is the deputy co-chair of The National MDS Study.



MDS Diagnosis and risk stratification: Gettingafacelift

Rami Komrokji Preview
Amy DeZern Preview
Amy DeZern Presentation
Q&A
Amy DeZern Slides

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Amy Dezern

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Pierre_Fenaux
Pierre Fenaux

Hôpital Saint Louis, Paris, France

Pierre Fenaux, is professor of hematology and head of the hematology department at hospitals St Louis, Robert Debré and Avicenne  (belonging to Assistance Publique- Hôpitaux de Paris Hospital network). He is also part of  Inserm research  unit n° 944, at Hôpital St Louis, Paris, for his laboratory research activity  

He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML, mainly AML in the elderly and acute promyelocytic leukemia, APL ). 

He is a founding member and chairman of the French speaking MDS group (Groupe Francophone des Myélodysplasies or GFM) and of the French APL group (GT-LAP).

Luspatercept: where to fit the new kid on the block?

Pierre Fenaux Presentation
Pierre Fenaux Slides
May Q&A Session
Pierre FENAUX summary

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Pierre Fenaux

Hospital Saint Louis, Paris, France

Mikkael Sekeres
Mikkael Sekeres

University of Miami Miller School of Medicine, Florida, USA

Dr Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. He earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr Sekeres completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. He is chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome (MDS) International Foundation, and formerly chaired the Oncologic Drugs Advisory Committee of the F.D.A, the MDS Research Fund of the Dresner Foundation, and the Cleveland Clinic Enterprise Pharmacy & Therapeutics Committee, where he was also Vice-chair for Clinical Research of the cancer center. An invited speaker at numerous meetings, grand rounds, and conferences, Dr Sekeres is a member of the American Society of Hematology, where he has served on the Executive Committee, the American Society of Clinical Oncology, and the Southwest Oncology Group—Leukemia Committee. His research focuses on patients with MDS and older adults with acute myeloid leukemia, and he has been the national and international primary study investigator on several phase I/II/III trials. He is the author or co-author of over 350 manuscripts and 650 abstracts published in leading journals such as NEJM, Blood, Journal of Clinical Oncology, Nature Genetics, Cancer Cell, Journal of the National Cancer Institute, Journal of Clinical Investigation, PLoS One, and Leukemia. He was the inaugural editor-in-chief of the ASH Clinical News magazine; he is on the editorial board of several journals; has written over 50 essays for The New York Times; and has authored 7 books, including When Blood Breaks Down: Life Lessons from Leukemia (MIT Press 2020).

HMA: Do we know how and when to use in MDS after 2 decades?

Mikkael Sekeres Intro
Mikkael Sekeres Presentation
Rami Komrokji Intro
Q&A
Mikkael Sekeres Slides

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Mikkael Sekeres

University of Miami Miller School of Medicine, Florida, USA

19. Bart Scott
Bart Scott

University of Washington Medical Center, Seattle, Washington, USA

Bart Scott is a medical oncologist at Fred Hutchinson Cancer Research Center in Seattle, Washington. He is Professor of Medicine in the Division of Oncology at the University of Washington Medical Center and Director of Myeloid Malignancies at the Seattle Cancer Center Alliance. He is board certified in internal medicine and medical oncology by the American Board of Internal Medicine. Dr. Scott received his medical degree from the University of Alabama. He then completed his internship and residency at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his fellowship in medical oncology at the University of Washington in Seattle. Dr. Scott has participated in a number of studies involving myelodysplastic syndromes and myeloproliferative disorders. He has published numerous articles in journals such as American Journal of Medicine ,  Leukemia & Lymphoma ,  Blood , and  Journal of Clinical Oncology . He is also a reviewer for  New England Journal of Medicine ,  British Journal of Haematology ,  Journal of the National Comprehensive Cancer Network , and  Haematologica , among others. Dr. Scott has been an invited lecturer on the management and treatment of myelodysplastic syndromes and transplantation for bone marrow failure. He is a member of the American Medical Association, the American Society of Hematology, the American Society of Clinical Oncology, and the Southwest Oncology Group, among many others.

Allogeneic stem cell transplant: how can we cure more patients?

Bart Scott Intro
Bart Scott Presentation
Q&A
Bart Scott Slides

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Bart Scott

University of Washington Medical Center, Seattle, Washington, USA

20. Guillermo-Garcia Manero
Guillermo Garcia- Manero

MD Anderson Cancer Center, Houston, Texas, USA

Dr. Guillermo Garcia-Manero is the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. He also serves as the Chief of the Section of Myelodysplastic Syndromes, Vice Chairman for Translational Research, Leader of the AML/MDS Moon Shot Program and Program Director of the Leukemia Fellowship Program (September 2019). He recently was elected as Chair-elect of the Faculty Senate of the University of Texas MD Anderson Cancer Center, which also starts in September 2019.

Dr. Garcia-Manero was born in Spain and received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London, UK. From 1993-1996, he performed his internship and residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, PA. He then continued his training with a fellowship in Hematology and Medical Oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center, also at Thomas Jefferson University Hospital, where he served as chief fellow. In 1999, he became Assistant Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center where he has remained for the rest of his academic career.

Dr. Garcia-Manero focuses on the understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for patients with these disorders. His work has been funded by NIH, DoD, LLS, CPRIT, and the MDS/AML Moon Shot project. He has co-authored over 682 manuscripts. His last H-index is 119 and his i10-Index is 630 with over 58,000 citations to his work. Currently, he is PI or Co-PI on over 25 active clinical trials focusing on AML and MDS. He directs what is likely the largest single institution unit for patients with
MDS in the world, with over 400 patients referred annually, and maintains one of the busiest clinics at MD Anderson. The Section of MDS is comprised of leukemia faculty dedicated to care for patients with MDS and two research laboratories directed by Dr. Colla and Dr. Wei. In addition, the section coordinates the work of over 15 research nurses. Dr. Garcia-Manero has received a number of significant awards, such as The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research and the Emil J. Freireich Award for Excellence in Translational Research at MD Anderson. He has also been recognized as one of the Best Doctors
in America each year since 2007. He has trained over 100 fellows and post doctoral fellows and has been a speaker at multiple national and international forums.

Role ofvenetoclax in MDS: Playing out of the box?

Rami Komrokji Intro
Guillermo Garcia-Manero Intro
Guillermo Garcia-Manero Presentation
Q&A

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Guillermo Garcia- Manero

MD Anderson Cancer Center, Houston, Texas, USA

27. David Sallman
David Sallman

Moffitt Cancer Center, Tampa, Florida, USA

David Sallman, MD, is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, FL. His clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies for patients with MDS and AML, based on the underlying mutational drivers of each disease. He has authored numerous articles, books, book chapters, and abstracts and serves as reviewer for multiple journals. In 2017, he received the Young Investigator Grant from the MDS Foundation. 

Novel agents for higher risk MDS: be on the look?

Rami Komrokji Intro
David Sallman Intro
David Sallman Presentation
Q&A
David Sallman Slide

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

David Sallman

Moffitt Cancer Center, Tampa, Florida, USA

16. Valeria Santini
Valeria Santini

University of Florence, Italy

Valeria Santini is Associate Professor of Hematology at the University of Florence, Italy.  She runs the MDS Unit- Hematology- Department of Experimental and Clinical Medicine- AOU Careggi, University of Florence. Her interests are focused on clinical and translational research in MDS and elderly AML. Professor Santini is President of the Scientific Committee of Fondazione Italiana per lo studio delle sindromi mielodisplastiche (FISiM) and Italian Network of MDS Registries. She belongs to ASH, EHA and MDS Foundation. She is also an author of more than 200 peer-reviewed papers published in international journals, she is member of the Editorial board of Blood journal, and documented reviewer for high impact factor scientific journals. She has been an invited speaker at numerous international meetings including the American Society of Clinical Oncology (ASCO 2007: educational session on MDS), American Society of Hematology (ASH 2012, ASH 2016: educational sessions on MDS), European Haematology Association (EHA 2016, EHA 2020, EHA 2022: Educational sessions on MDS) and national haematology societies of several countries.

Managing isolated neutropenia and thrombocytopenia in Lower risk MDS

Rami Komrokji Intro
Valeria Santini Intro
Valeria Santini Presentation
Q&A
Valeria Santini Slide

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Valeria Santini

University of Florence, Italy

Yazan Migdady

Yazan Migdady

Dr.Migdady has done blood bank fellowship at Stanford in addition to hematology & oncology training at the National Institutes of health program prior to joining the bone marrow transplant team at the Knight Cancer Institute.

Dr.Migdady specializes in caring for patients with malignant hematologic diseases and bone marrow transplantation.

Dr.Migdady’s clinical interest is in acquired and inherited bone marrow failure syndromes and malignant myeloid neoplasms in adult population. As an oncology immunotherapist, Dr.Migdady is working on developing novel cellular therapy for myeloid malignancies and solid tumors. 

Immunosuppressive therapy in MDS

Rami Komrokji Intro
Yazan Migdady Intro
Yazan Migdady Presentation
Q&A

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Yazan Migdady

Oregon Health & Science University, Portland, Oregon, USA

Hetty Carraway
Hetty Carraway

Cleveland Clinic, Ohio, USA

Dr. Hetty Caraway serves as the Director of the Leukemia Program and the Vice Chair of Strategy and Enterprise Development at the Taussig Cancer Institute at the Cleveland Clinic. Dr. Carraway received her medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts. She completed her internship and residency in internal medicine, and her Hematology-Medical Oncology fellowship at Johns Hopkins University in Baltimore, Maryland. In addition to her medical training, Dr. Carraway earned an MBA from the Carey Business School at Johns Hopkins University in the Business of Health. She is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Carraway is an active member of numerous professional organizations including the American Society of Hematology (ASH), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Southwest Oncology Group (SWOG), and the America College of Physicians, among others. She serves as the Vice Chair on the Committee on Training at ASH.  Dr. Carraway has co-authored numerous peer-reviewed publications, review articles, editorials, abstracts and book chapters. She is nationally sought for her expertise in hematologic malignancies (AML, ALL and MDS/MPN and bone marrow disorders). As a translational clinical scientist, Dr. Carraway’s research is focused on experimental therapeutics of acute leukemias and myeloid neoplasms. 

Novel agents for lower risk MDS: be on the look?

Rami Komrokji Intro
Hetty Carraway Intro
Hetty Carraway Presentation
Q&A

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Hetty Carraway

Cleveland Clinic, Ohio, USA

Andrew Brunner

Andrew Brunner

Massachusetts General Hospital, Boston, USA

Myelodysplastic syndromes are disorders of the bone marrow associated with bone marrow failure and a risk of progression to acute myeloid leukemia. My clinical area of focus and research projects are focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. The therapies available for patients with MDS have not changed in the last decade, and there is critical need to develop new agents and identify the patients most likely to benefit from a given chemotherapy. I am involved in clinical trials for all stages of MDS with an overall goal of tailoring treatment to improve the outcomes of these patients.

Response to treatment in MDS: how to assess benefit in clinical trials and practice

Rami Komrokji Intro
Andrew Brunner Intro
Andrew Brunner Presentation
Q&A

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Andrew Brunner

Massachusetts General Hospital, Boston, USA